^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Small Cell Lung Cancer
    Regimen:CAV (cyclophosphamide + pegylated liposomal doxorubicin + vincristine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    04/14/2021
    Excerpt:
    Recommendations: Either oral or i.v. topotecan is recommended for SCLC patients with platinum-resistant or -sensitive relapse; CAV is an alternative option [II, B].
    DOI:
    10.1016/j.annonc.2021.03.207
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Small Cell Lung Cancer: Other Recommended Regimen cyclophosphamide /doxorubicin/vincristine (CAV)